ReviewCurrent neurology and neuroscience reports2018
The Role of Tau Imaging in Parkinsonian Disorders.
Review in Current neurology and neuroscience reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The significance of cerebellar contributions in early-life through aging.Frontiers in computational neuroscience · 2024Article
- Tau in Atypical Parkinsonisms: A Meta-Analysis of in Vivo PET Imaging Findings.Movement disorders clinical practice · 2023Review
- Molecular Imaging in Parkinsonian Disorders-What's New and Hot?Brain sciences · 2022Review
- "Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Review
- Imaging Familial and Sporadic Neurodegenerative Disorders Associated with Parkinsonism.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
- IntegratedFrontiers in aging neuroscience · 2021Article
- The Design and Application of an Appropriate Parkinson's Disease Animal Model in Regenerative Medicine.Advances in experimental medicine and biology · 2021Review
- From molecules to system failure: translational frontiers of multimodal imaging in neurodegenerative diseases.European journal of nuclear medicine and molecular imaging · 2019Article
- [Propofol combined with hypoxia induces cognitive dysfunction in immature ratsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewDifferential diagnosis of atypical Parkinson syndromes (APS) is difficult as clinical presentations may vary and as there is a strong overlap between disease entities. Aggregations of misfolded and hyperphosphorylated tau proteins are the common denominator of many of these diseases. RECENT
findingsSeveral tau targeting positron emission tomography (PET) tracers have been evaluated as possible biomarkers in APS in the recent years. For Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration, promising results have been reported with regard to the ability to detect the presence of disease and to discriminate patients from controls. However, the discussion about the specificity of the first-generation radiotracers and their value in the clinical context is ongoing. A combined interpretation of signal strength and distribution pattern in PET scans with first- and second-generation tracers may be helpful in clinical diagnosis and follow-up of patients with APS.
Indexed as
Identifiers
30293094What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.